Previous Next

2024-02-07

Ibudilast in multiple sclerosis

Neurology

Ibudilast, which targets IL-1beta, TNF-alpha and IL-6, has shown beneficial effects on various imaging findings in progressive multiple sclerosis. In this Phase II clinical trial, researchers evaluated the benefit of this treatment on the evolution of certain MS neurological lesions over a 96-week period. A total of 195 patients with progressive MS were followed at 28 different sites, and randomized to ibudilast or placebo. Ibudilast improved patients' MRI findings at two levels, suggesting a neuroprotective effect of this new treatment in progressive MS.

Source(s) :
Kunio Nakamura et al. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Mult Scler. 2024 Jan 29:13524585231224702. ;

Last press reviews


COVID-19 and coagulation parameters: a link to mortality?

The COVID-19 pandemic, caused by SARS-CoV-2, has led to millions of deaths...

Resistance training and Multiple Sclerosis: a solution to improve function and quality of life?

Multiple sclerosis (MS) is a chronic autoimmune disease of the central ner...

Endometriosis: the Impact of hormones, sexual practice, and surgical treatments

Endometriosis is a chronic inflammatory disease modulated by estrogen leve...